Podrobno

EULAR study group on 'MHC-I-opathy' : identifying disease-overarching mechanisms across disciplines and borders
ID Kuiper, Jonas Jan Willem (Avtor), ID Vidović Valentinčič, Nataša (Avtor), ID Turkstra, Franktien (Avtor), et al.

.pdfPDF - Predstavitvena datoteka, prenos (790,03 KB)
MD5: 75B538544B87423EF79E1F3C4B6B5998
URLURL - Izvorni URL, za dostop obiščite https://ard.eular.org/article/S0003-4967(24)00398-4/fulltext Povezava se odpre v novem oknu

Izvleček
The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8$^{+}$ T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway. Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.

Jezik:Angleški jezik
Ključne besede:psoriatic arthritis, Behçet syndrome, immune system diseases, ankylosing spondylitis
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2023
Št. strani:Str. 887-896
Številčenje:Vol. 82, iss. 7
PID:20.500.12556/RUL-182309 Povezava se odpre v novem oknu
UDK:616-002
ISSN pri članku:0003-4967
DOI:10.1136/ard-2022-222852 Povezava se odpre v novem oknu
COBISS.SI-ID:275985411 Povezava se odpre v novem oknu
Datum objave v RUL:07.05.2026
Število ogledov:383
Število prenosov:222
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Annals of the Rheumatic Diseases
Skrajšan naslov:Ann. Rheum. Dis.
Založnik:British Medical Association
ISSN:0003-4967
COBISS.SI-ID:24967936 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:psoriatični artritis, Behçetov sindrom, bolezni imunskega sistema, ankilozirajoči spondilitis

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj